A $101 million print forces the CV debate
Priced LP-led trades give buyers a benchmark to use against Amulet's unpriced US Fertility continuation vehicle.
The secondaries market finally got a number this week, though not from the deal everyone was watching. A bank position changed hands at $101 million and a Dutch pension fund reached an agreement on another LP-led trade, both with prices attached, while the continuation vehicle Amulet Capital Partners closed for US Fertility carried none.
A bank selling a fund position is often selling for balance-sheet reasons rather than an asset-specific view, making its print a useful gauge of the liquidity discount in the market; a Dutch pension fund reaching an agreement is similarly motivated by allocation or liquidity needs, not necessarily a negative view of the underlying fund. These are rational liquidity events, which is exactly why they can anchor a buyer's underwriting.
Continuation vehicles are the secondaries market's most visible growth product and also its least transparent pricing event: a GP rolls a portfolio asset into a new vehicle, gives existing limited partners the choice to cash out or roll over, and sets terms based on its own valuation work, with no auction, no third-party bid, and typically no published price. The sponsor's mark is the number, and it is a number the sponsor has every reason to keep at or above the last reported NAV—simply the structure of the product.
Amulet's US Fertility CV closed this week with no published price, placing it directly inside that structure. Buyers evaluating the deal have to decide whether to accept the sponsor's mark or demand an anchor, and the bank and pension prints give them the anchor. If a regulated bank accepted a price that implied a discount to the last marks on comparable assets, the question becomes inescapable: why should a continuation vehicle close at or above the sponsor's mark? That question, asked once, changes every CV negotiation that follows.
Two reference points
The bank sale is small in absolute terms—$101 million is not a market-moving print—but its significance lies in its availability, because most LP-led trades are private, negotiated one-off transactions whose terms are never published. That this week produced a public record of both the bank sale and a Dutch pension fund agreement is unusual, and buyers can now say, with a straight face, that there is a recent, observable clearing level for a certain class of LP-led supply—a rare commodity in a market that runs on confidentiality.
The two reference points this week expose two underwriting models: in an LP-led sale, the buyer asks what a motivated seller will accept today, and the answer is a balance-sheet discount, a price that clears the seller's need for liquidity rather than the asset's long-term value; in a GP-led continuation vehicle, the buyer is asked to accept the sponsor's underwriting, a price that has not been tested by an arm's-length transaction. The first model produces a number, the second produces a promise, and this week, for once, the market has both.
That asymmetry is why the unpriced CV is now under pressure: Amulet will likely have to defend its mark against the bank's clearing price and the pension fund's agreement, and against the widening spread between what an LP can get by selling now and what a GP promises by rolling. The bank and pension prints are small but real, and in a market where most GP-led deals are priced in the dark, even a thin public reference changes the vocabulary—the next time a sponsor presents an unpriced CV, buyers can point to a number and ask what this asset would clear at in an LP-led sale.
The unpriced close
That pressure is justified: for years, continuation vehicles have allowed sponsors to extend hold periods without ever marking the asset to a third-party bid, producing a secondaries market where the most important prices are the ones least likely to be published. The bank and pension prints this week do not reset the whole market, but they give buyers a vocabulary they have lacked, and the question they pose is not rhetorical—it is the beginning of price discovery.
The practical consequence for Amulet is straightforward: the sponsor can no longer close its continuation vehicle purely on the strength of its own marks, because this week produced two external data points that any serious buyer will bring into the room. The unpriced close was once a feature of GP-led deals—it let sponsors bridge valuation gaps without a public accounting—but now it looks like a liability, because the absence of a price is no longer neutral when there is a price right next to it.
Watch whether Amulet discloses a price in the coming weeks, and watch whether the next continuation vehicle tries to anchor its pricing to these LP-led prints. If it does, this week will be remembered as the moment the secondaries market started demanding a mark-to-market reference from its sponsors. If it does not, the unpriced CV will have survived another week, but the comparison will linger—and comparisons have a way of becoming benchmarks.